NeoGraph Analytics
BiotechnologyGlobal2026 – 2032

Bispecific Antibodies Market Size, Share & Forecast 2026-2032

Published bispecific antibody market sizes spread 3.49x. Disclosed FY2025 revenue of $14.45bn shows the gap is one scope call: do Hemlibra and Vabysmo count?

Revenue, 2026

$14.4B

Forecast, 2032

$32.9B

CAGR, 2026-2032

14.7%

Report Coverage

Global

Code: bispecific-antibodies-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Published estimates of the bispecific antibody market put its 2025 size between $8.93 billion and $31.17 billion - a 3.49x spread. The explanation is not vintage, geography or growth. It is a single classification decision that almost no published report states plainly: whether a bispecific antibody counts when it is not an oncology drug.

Emicizumab (Hemlibra) binds factor IXa and factor X. Faricimab (Vabysmo) binds VEGF-A and Ang-2. Both are bispecific antibodies by construction, and in FY2025 Roche reported them at CHF 4,754 million and CHF 4,102 million respectively - about $10.66 billion at the Swiss Federal Tax Administration's 2025 annual average of CHF 0.83053 per USD. Every approved oncology bispecific whose revenue we could find disclosed - Blincyto $1,559 million, Imdelltra $627 million, Tecvayli $670 million, Talvey $463 million, Epkinly/Tepkinly $468 million - sums to $3.79 billion. Non-oncology is therefore 74% of the disclosed total of $14.45 billion, and the two readings of this market differ by roughly 3.8x.

That arithmetic does more than explain the spread; it adjudicates it. Roots Analysis's $8.93 billion and Market Research Future's $10.50 billion are both below Hemlibra plus Vabysmo on their own, so neither can be describing the full format - yet both are more than twice the oncology-only total, so neither matches that reading either. Fortune Business Insights's $31.17 billion is 2.16x every dollar of bispecific revenue anyone discloses, including products we had to leave out of the sum, so it cannot be product revenue. Astute Analytica's $14.4 billion for 2025 agrees with the bottom-up total to within 0.3%, which is why this report uses its growth rate.

The $14.45 billion base is a floor: Rybrevant, Columvi, Lunsumio and Lynozyfic are approved and sold but not individually disclosed. A reader checking any bispecific forecast should start by asking which of these products it counts.

02

Key Highlights

1

Published 2025 base-year estimates spread 3.49x, from $8.93 billion to $31.17 billion

2

Seven approved bispecific antibodies disclosed $14.45 billion of FY2025 revenue, 74% of it outside oncology

3

Hemlibra (CHF 4,754m) and Vabysmo (CHF 4,102m) alone are about $10.66 billion, nearly 3x all approved oncology bispecifics combined

4

Two published estimates are below Hemlibra plus Vabysmo on their own and so cannot describe the full format

5

Fortune Business Insights's $31.17 billion is 2.16x all disclosed bispecific revenue, so it cannot be product revenue

6

Astute Analytica's $14.4 billion for 2025 matches the bottom-up disclosed sum to within 0.3%

7

The base is a floor: Rybrevant, Columvi, Lunsumio and Lynozyfic are approved but not individually disclosed

03

Market Overview

Market Context

A bispecific antibody is one molecule with two different binding sites, and that single engineering fact supports two unrelated businesses. In the first, the second binding arm replaces a missing biological bridge: emicizumab substitutes for activated factor VIII by holding factor IXa and factor X together, turning a haemophilia A patient's intravenous regimen into a subcutaneous one. In the second, the second arm recruits a killer - a CD3 bispecific grabs a T cell with one hand and a tumour antigen with the other, forcing a synapse that would not otherwise form. These have almost nothing in common commercially. The haemophilia and retinal products are chronic, outpatient, prescribed by non-oncologists and measured in years of therapy per patient. The T-cell engagers are fixed-duration or until-progression, initiated under supervision because of cytokine release syndrome, and concentrated in relapsed or refractory haematological malignancy where the eligible pool is small and already crowded. That is why a market sized as 'bispecific antibodies' is sensitive to a definition rather than to the economy. It is also why the oncology side looks disappointing in absolute terms despite excellent growth rates: Blincyto was approved in 2014 and is still the largest disclosed oncology bispecific at $1,559 million, while newer entrants such as Imdelltra and Talvey are growing from bases in the hundreds of millions. The format is proven; the commercial scale is still mostly in non-oncology.

Published estimates of the bispecific antibody market spread 3.49x at the 2025 base year, from $8.93 billion to $31.17 billion. The explanation is one classification decision: whether non-oncology bispecifics count. Emicizumab and faricimab are bispecific antibodies by construction, and in FY2025 they alone disclosed $10.66 billion of revenue - 74% of all disclosed bispecific revenue and nearly three times every approved oncology bispecific combined. Summing seven disclosed products gives $14.45 billion for FY2025, which this report carries as the 2026 base, reaching $32.90 billion by 2032 at 14.7%.

Market Stage

Growth

Adoption Level

Established in haemophilia and retinal disease, expanding in haematological oncology

Key Trends

Published 2025 base-year estimates spread 3.49x ($8.93B to $31.17B), and the gap is a definition of the category, not a disagreement about growthNon-oncology bispecifics are 74% of disclosed revenue: Hemlibra at CHF 4,754 million and Vabysmo at CHF 4,102 million, about $10.66 billion combinedAll approved oncology bispecifics we could find disclosed total just $3.79 billion in FY2025, led by Blincyto at $1,559 millionTwo published estimates ($8.93B and $10.50B) are below Hemlibra plus Vabysmo alone, so they cannot describe the whole formatOne published estimate, Astute Analytica's $14.4 billion for 2025, agrees with the disclosed sum to within 0.3%The newest T-cell engagers are scaling fast from small bases: Imdelltra reached $627 million in its second full year and Talvey grew 61.3%
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 14.7%

Base Year (2026)

$14.4B

Forecast (2032)

$32.9B

CAGR (2026-2032)

14.7%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$14.45B
2027$16.57B
2028$19.01B
2029$21.80B
2030$25.01B
2031$28.69B
2032$32.90B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR between published endpoints. How these figures are produced.
Forecast Analysis

The series starts at $14.45 billion for 2026 - the FY2025 disclosed revenue of seven approved bispecific antibodies, carried forward unchanged because 2026 revenue is not yet disclosed - and compounds at 14.7% to $32.90 billion by 2032. The intermediate years are interpolation on that single rate. The rate is Astute Analytica's published 2026-2035 figure, chosen for a specific reason: Astute's own published base of $14.4 billion for 2025 is the only one that reconciles with the bottom-up disclosed total. Using a rate from a house whose base our arithmetic rules out would be mixing an audited level with a slope derived from a different market. The composition of that growth is the part to watch. Roughly three-quarters of the base is two mature franchises growing in the high single digits - Hemlibra grew 11% in FY2025 - and facing biosimilar and gene-therapy pressure later in the period. The high-growth quarter is oncology, where Talvey grew 61.3% and Imdelltra reached $627 million in its second full year, but from bases small enough that even excellent percentage growth adds limited absolute revenue before 2030. A forecast above the mid-teens therefore requires either earlier-line oncology labels or a second non-oncology franchise of Hemlibra's scale, and should name which.

05

Market Dynamics

  • Two very large non-oncology franchises compounding on a chronic dosing model: Hemlibra grew 11% to CHF 4,754 million in FY2025
  • Off-the-shelf administration, which lets a T-cell engager reach patients who cannot wait for autologous cell therapy manufacturing
  • Rapid launch curves in myeloma and small cell lung cancer: Talvey up 61.3% and Imdelltra at $627 million in FY2025
  • Subcutaneous and fixed-duration regimens, which move administration out of infusion centres
  • Format maturity - stable, manufacturable IgG-like bispecifics are now a routine engineering choice rather than a research problem
06

Market Segmentation

By Type

  • T-cell engagers (CD3 bispecifics)
  • Non-immune-cell-engaging IgG-like bispecifics
  • Dual receptor blockers
  • Fragment-based and non-IgG formats

By End User

  • Academic and specialty cancer centres
  • Haemophilia treatment centres
  • Retina and ophthalmology practices
  • Community oncology and infusion centres

By Application

  • Haematological malignancy
  • Solid tumours
  • Haemophilia
  • Retinal disease
  • Autoimmune and inflammatory disease
07

Competitive Landscape

R

Roche

Switzerland

Largest disclosed bispecific revenue, almost entirely non-oncology

Reported Hemlibra (emicizumab) at CHF 4,754 million for FY2025, up 11% from CHF 4,503 million, and Vabysmo (faricimab) at CHF 4,102 million - together about $10.66 billion at the 2025 annual average rate, or 74% of all bispecific revenue disclosed anywhere. Also markets Columvi and Lunsumio, neither of which Roche breaks out in its FY2025 release. No market share is disclosed.

A

Amgen

United States

Largest disclosed oncology bispecific franchise

Reported Blincyto at $1,559 million for FY2025 (US $1,049 million, up 31%; rest of world $510 million, up 23%) and Imdelltra at $627 million including $234 million in the fourth quarter. Blincyto, approved in 2014, remains the single largest disclosed oncology bispecific more than a decade later.

J

Johnson & Johnson

United States

Broadest approved myeloma bispecific portfolio

Reported Tecvayli at $670 million for FY2025 (up 22.1% from $549 million) and Talvey at $463 million (up 61.3% from $287 million). Also markets Rybrevant, an EGFR-MET bispecific, which J&J reports jointly with Lazcluze rather than separately, so its annual revenue is not isolable from public disclosure.

G

Genmab

Denmark

Format specialist, partnered commercialisation

Reported global Epkinly/Tepkinly (epcoritamab) net sales of $468 million for FY2025 against $281 million in FY2024, a 67% increase, of which $379 million was booked by Genmab in the US and Japan. Commercialised in partnership with AbbVie, which is paid a profit share.

A

AbbVie

United States

Partner on an approved lymphoma bispecific

Shares in Epkinly/Tepkinly economics through its collaboration with Genmab. AbbVie's own disclosure of the product is limited to the profit-share line, which is why this report counts Genmab's global in-market figure once rather than summing both partners.

R

Regeneron Pharmaceuticals

United States

Recent entrant in myeloma

Markets Lynozyfic (linvoseltamab), among the most recent bispecific approvals. Its revenue is not included in the $14.45 billion aggregate used here, which makes that figure a floor rather than a market total.

08

Regulatory Landscape

FDA Biologics License Application pathway under section 351 of the Public Health Service Act, the route for every approved bispecific antibodyFDA guidance on bispecific antibody development programmes, which sets expectations for characterising each binding arm and the combined constructFDA accelerated approval pathway, used for several T-cell engagers in relapsed or refractory haematological malignancy and carrying confirmatory trial obligationsRisk Evaluation and Mitigation Strategy programmes applied to T-cell engagers for cytokine release syndrome and neurological toxicity, which determine where therapy may be initiatedEMA centralised marketing authorisation, including conditional authorisation used for bispecifics in relapsed settingsBiosimilar pathways under the Biologics Price Competition and Innovation Act, relevant to the large non-oncology franchises over the forecast period
09

Research Methodology

Primary research

  • No primary interviews were conducted for this edition. This report is a synthesis of audited company disclosures, published third-party estimates and an official exchange rate list, and is labelled as such rather than implying fieldwork that did not occur.

Secondary research

  • Amgen Form 10-K FY2025 product sales table: Blincyto US $1,049m (+31%) and rest of world $510m (+23%); total product sales $35,148m
  • Amgen Fourth Quarter and Full Year 2025 results, February 2026: Imdelltra $627m for the full year, $234m in Q4
  • Johnson & Johnson FY2025 annual report sales table: Tecvayli $670m (2024 $549m), Talvey $463m (2024 $287m); company sales $94,193m
  • Genmab 2025 Annual Report: global Epkinly/Tepkinly net sales $468m (2024 $281m), Genmab-booked US and Japan sales $379m
  • Roche Finance Report 2025 and FY2025 results release of 29 January 2026: Hemlibra CHF 4,754m (+11%), Vabysmo CHF 4,102m, group sales CHF 61.5bn
  • Swiss Federal Tax Administration 2025 annual average rate of CHF 0.83053 per USD, used for every Roche conversion in this report
  • Published market estimates from Fortune Business Insights (2025), Astute Analytica (2025), BCC Research, Market Research Future (2025) and Roots Analysis (2025)

Validation: The headline base is a bottom-up sum of FY2025 disclosed worldwide product revenue for seven approved bispecific antibodies: Blincyto $1,559m, Imdelltra $627m, Tecvayli $670m, Talvey $463m, Epkinly/Tepkinly $468m, plus Hemlibra CHF 4,754m and Vabysmo CHF 4,102m converted at the Swiss Federal Tax Administration 2025 annual average of CHF 0.83053 per USD, giving $5,724m and $4,939m. The total is $14,450m, or $14.45 billion, of which 74% is non-oncology. Rybrevant, Columvi, Lunsumio and Lynozyfic are excluded because their annual revenue is not individually disclosed, so the figure is a floor. The test identifies which published estimates can be product revenue: Roots Analysis's $8.93 billion and Market Research Future's $10.50 billion are both below Hemlibra plus Vabysmo alone and so cannot cover the format, while Fortune Business Insights's $31.17 billion is 2.16x all disclosed bispecific revenue and therefore cannot be product revenue either. Astute Analytica's $14.4 billion agrees with the disclosed sum to within 0.3%, and its 14.7% rate is used for the forecast. This is a plausibility test, not a market estimate, and no methodology behind any published figure was inspected.

10

Strategic Takeaways

Before using any bispecific antibody forecast, check whether it counts Hemlibra and Vabysmo - that one decision moves the market by roughly 3.8x

Two of the five mainstream published estimates are below Hemlibra plus Vabysmo alone, so they cannot be describing the whole format

The oncology side is only about a quarter of disclosed revenue

high growth rates on small absolute bases

Treat any vendor share percentage as unsourced - even a careful bottom-up total is a floor, because several approved products are not individually disclosed

Model the non-oncology franchises for biosimilar and gene-therapy pressure late in the period, not for indefinite compounding

11

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.